Taysha Gene Therapies (TSHA) Non-Current Debt (2021 - 2026)

Taysha Gene Therapies has disclosed Non-Current Debt across 6 years of filings, most recently posting $49.0 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $49.0 million, up 15.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.0 million (up 15.33% YoY), and the FY2025 annual result was $50.1 million, up 14.03% from the prior year.
• Non-Current Debt came in at $49.0 million for Q1 2026 at Taysha Gene Therapies, down from $50.1 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $50.9 million in Q3 2025 to a low of $37.4 million in Q1 2022.
• The 5-year median for Non-Current Debt is $40.5 million (2023), against an average of $41.5 million.
• Across the five-year window, Non-Current Debt jumped 35.82% in 2022 and dropped 1.35% in 2024, its largest moves.
• Taysha Gene Therapies' Non-Current Debt stood at $38.0 million in 2022, then increased by 6.69% to $40.5 million in 2023, then increased by 8.48% to $43.9 million in 2024, then gained by 14.03% to $50.1 million in 2025, then retreated by 2.29% to $49.0 million in 2026.
• The last three Non-Current Debt figures came in at $49.0 million (Q1 2026), $50.1 million (Q4 2025), and $50.9 million (Q3 2025), per Business Quant data.